[go: up one dir, main page]

MX2016013913A - Compuesto heterociclico biciclico o triciclico novedoso. - Google Patents

Compuesto heterociclico biciclico o triciclico novedoso.

Info

Publication number
MX2016013913A
MX2016013913A MX2016013913A MX2016013913A MX2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A
Authority
MX
Mexico
Prior art keywords
atom
nitrogen atom
triciclic
novedous
heterociclic
Prior art date
Application number
MX2016013913A
Other languages
English (en)
Other versions
MX381182B (es
Inventor
Hideki Horiuchi
Kenji Fukunaga
Okuyama Masahiro
Norimitsu Hayashi
Usui Kenji
Iijima Daisuke
Itagaki Noriaki
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54332502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2016013913A publication Critical patent/MX2016013913A/es
Publication of MX381182B publication Critical patent/MX381182B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto heterocíclico bicíclico o tricíclico novedoso representado por la fórmula (I) (ver Fórmula) en donde el anillo A es un grupo aromático opcionalmente sustituido, uno de X1 y X2 es un átomo de carbono, y el otro es un átomo de nitrógeno, X3 es un átomo de nitrógeno, o CR2, X4 es un átomo de nitrógeno, o CR3, X5 es un átomo de azufre, o -CH=CH-, Z1 es un átomo de oxígeno, -C(R6)(R7)-, -NH-, -C(R6)(R7)-NH-, -NH-C(R6)(R7)-, -C(R6)(R7)-O-, -O-C(R6)(R7)-, o un enlace sencillo, uno de Z2 y Z3 es CH y el otro es un átomo de nitrógeno, o ambos son átomos de nitrógeno, y otros símbolos son tal como se definen en la DESCRIPCIÓN, o una sal farmacológicamente aceptable del mismo.
MX2016013913A 2014-04-23 2015-04-22 Compuesto heterociclico biciclico o triciclico novedoso. MX381182B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014089185 2014-04-23
PCT/JP2015/062165 WO2015163339A1 (ja) 2014-04-23 2015-04-22 新規二環性または三環性複素環化合物

Publications (2)

Publication Number Publication Date
MX2016013913A true MX2016013913A (es) 2016-11-15
MX381182B MX381182B (es) 2025-03-12

Family

ID=54332502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013913A MX381182B (es) 2014-04-23 2015-04-22 Compuesto heterociclico biciclico o triciclico novedoso.

Country Status (13)

Country Link
US (1) US10065972B2 (es)
EP (2) EP3683222B1 (es)
JP (1) JP6442485B2 (es)
KR (1) KR102458990B1 (es)
CN (1) CN106661017B (es)
AU (1) AU2015251207B2 (es)
BR (1) BR112016024455B1 (es)
CA (1) CA2946702C (es)
MX (1) MX381182B (es)
PH (1) PH12016502091B1 (es)
RU (1) RU2702113C2 (es)
TW (1) TWI693227B (es)
WO (1) WO2015163339A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372601B1 (en) * 2015-10-22 2022-09-21 Mitsubishi Tanabe Pharma Corporation Novel bicyclic heterocyclic compound
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
CN114728167B (zh) 2019-11-25 2024-03-19 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
BR112022020418A2 (pt) * 2020-04-08 2023-05-02 Remix Therapeutics Inc Compostos e métodos para modulação de splicing
EP4319872A4 (en) * 2021-04-05 2025-03-12 Inipharm, Inc. Thiazole/isothiazole hsd17b13 inhibitors and uses thereof
EP4416156A1 (en) * 2021-10-13 2024-08-21 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
CN114315760A (zh) * 2021-12-29 2022-04-12 内蒙古久日新材料有限公司 一种2-氯-1-（4-吗啉苯基）-1-丁酮的制备方法及其应用
CN115925618A (zh) * 2023-01-06 2023-04-07 河南省科学院化学研究所有限公司 一种2-(2,2,2-三氟乙氧基)-6-氯-3-氨基吡啶的合成方法
CN116574084A (zh) * 2023-04-17 2023-08-11 华南理工大学 一种噻吩衍生物及其合成方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519055A (en) 1993-08-06 1996-05-21 University Of Maryland At Baltimore Substituted kynurenines and process for their preparation
GB9716101D0 (en) * 1997-07-30 1997-10-01 Pharmacia & Upjohn Spa Fused heterocyclic compounds
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
MA33407B1 (fr) 2009-06-18 2012-07-03 Pfizer Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii
AU2011336214B2 (en) * 2010-12-01 2015-08-20 Pfizer Inc. KAT II inhibitors
CA2819106C (en) * 2010-12-01 2015-12-29 Pfizer Inc. Kat ii inhibitors
RU2014146509A (ru) 2012-06-15 2016-08-10 Пфайзер Инк. Ингибиторы кат ii

Also Published As

Publication number Publication date
US10065972B2 (en) 2018-09-04
EP3135674A4 (en) 2017-12-20
AU2015251207B2 (en) 2019-08-22
RU2016145602A (ru) 2018-05-23
KR20160144025A (ko) 2016-12-15
CN106661017A (zh) 2017-05-10
CN106661017B (zh) 2019-09-24
TW201602115A (zh) 2016-01-16
PH12016502091B1 (en) 2020-01-29
EP3135674A1 (en) 2017-03-01
RU2016145602A3 (es) 2018-11-14
CA2946702C (en) 2022-06-28
US20160376289A1 (en) 2016-12-29
BR112016024455A2 (pt) 2017-08-15
EP3683222A1 (en) 2020-07-22
CA2946702A1 (en) 2015-10-29
KR102458990B1 (ko) 2022-10-25
JP6442485B2 (ja) 2018-12-19
RU2702113C2 (ru) 2019-10-04
MX381182B (es) 2025-03-12
PH12016502091A1 (en) 2017-01-09
JPWO2015163339A1 (ja) 2017-04-20
WO2015163339A1 (ja) 2015-10-29
BR112016024455B1 (pt) 2023-02-07
AU2015251207A1 (en) 2016-12-08
TWI693227B (zh) 2020-05-11
EP3683222B1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
MX2016013913A (es) Compuesto heterociclico biciclico o triciclico novedoso.
CO2017013709A2 (es) Lactamas bicíclicas.
CO2017007635A2 (es) Nuevos compuestos bicíclicos
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
GT201200230A (es) Inhibidores del virus de la hepatitis c
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2021007665A (es) Metodos novedosos.
MX2016012984A (es) Derivados indol para uso en medicina.
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CR20120418A (es) Inhibidores de virus flaviviridae
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
PE20181007A1 (es) Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue
MX373196B (es) Inhibidores de histona desacetilasa novedosos.
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20120460A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
EA201691031A1 (ru) Синтез макроциклического трипептида, ингибирующего hcv ns3